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Rubella Epidemic
Strain, Greece,
1999
To the Editor: A recent extensive
study on global distribution of rubella
virus genotypes by Zheng et al. (1)
showed that most of the isolates test-
ed were rubella genotype I (RGI) and
that subgenotypes within RGI were
apparent. Of these subgenotypes,
three were currently active, one in the
United States and Latin America, one
in China represented by two speci-
mens, and one international subgeno-
type that originated in Asia and spread
to Europe and North America. More
RGI subgenotypes, which have not
yet been identified in specimen col-
lections, may be currently active. In
Zheng, et al. the distribution of rubel-
la subgenotypes is shown; Greece is
one of the four European countries
where only RGI viruses were found.
This letter provides more information
about rubella in Greece and the strain
that was responsible for the 1999 epi-
demic there. 
Rubella virus is endemic in Greece.
Vaccination in the private sector only
was introduced in 1981 with a mono-
valent rubella vaccine. In 1989, a sin-
gle dose of the measles-mumps-rubel-
la (MMR) vaccine was introduced in
the national vaccination program for
15-month-old infants. Because of the
rubella outbreak of 1993, the vaccina-
tion policy changed. In 1997, a second
vaccination was recommended for 11-
to 12-year-old children. However,
another major rubella epidemic
occurred in 1999, beginning in late
December 1998 and lasting until May
1999, with a peak in the number of
cases in January. During this period,
1,438 rubella cases were reported
throughout Greece; 765 were in the
northern part of the country. In previ-
ous rubella epidemics in Greece, chil-
dren were most affected. However, in
the 1999 epidemic, a higher incidence
rate was observed mostly among 15-
to 19-year-old persons (2). During this
epidemic, four cases of congenital
rubella syndrome were reported.
Because of this epidemic, the vaccina-
tion policy was revised. The new poli-
cy consists of two doses of the MMR
vaccine, one to be given at 15 months
of age and another to be given at 4–6
years of age (3). 
During the 1999 epidemic, oral
samples were collected from patients
within a week of the onset of symp-
toms. Most of the samples were sent
to Colindale, London, for testing; a
few of them were stored at –70°C in
our laboratory at the School of
Medicine, Aristotle University of
Thessaloniki, Thessaloniki, Greece.
In 1999, four universities in the
United Kingdom reported cases of
rubella infection. Greek students were
attending all of these universities; the
students had spent the Christmas hol-
idays in Greece and then returned to
the United Kingdom. The U.K. rubel-
la strains were identical to those of the
Greek epidemic strain (4). We ampli-
fied and sequenced a 143-bp segment
of the E1 gene by using reverse tran-
scription-nested polymerase chain
reaction from the samples stored in
our laboratory (5). All 10 samples
tested contained very similar or iden-
tical sequences, so we used one of
them as the epidemic rubella strain.
Comparing the Greek strain
(Thess1/GRE99, accession no.
AY540614) with rubella sequences
taken from GenBank, we found that it
belonged to the international
(1997–2000) rubella RGI subgeno-
type. Although the genome region
tested was short, the Greek rubella
strain was highly homologous to the
strains isolated from Germany in
1999 (G432/GER99, accession no.
AF551761) and from Italy in 1997
(6423/PV/ITA97, accession no.
AY161374). However, the Greek
strain had a genetic difference of
approximately 5% from strains isolat-
ed from Italy (4844/ITA93, accession
no. AY161364), the United Kingdom
(DNY/UNK93, accession no.
AF039131) in 1993, and Germany
(D075/GER92, accession no.
AF039118) in 1992 and (G696/
GER98, accession no. AY326342) in
1998. We also found that the Greek
strain differed by 6% from the
RA27/3 vaccine strain, predominantly
used for RGI. 
Zheng et al. (1) showed that the
RGI-ITA97 genotype strain was
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closely related to a genotypic group of
viruses isolated from the eastern
United States and two Caribbean
countries from 1999 to 2001 (6).
Results from our phylogenetic analy-
sis showed that Thess1/GRE99, as
well as strains G432/GER99 and
6423/PV/ITA97 (and the United
Kingdom 1999 strains), were cluster-
ing with strains FRI/BAH97 (acces-
sion no. AY326359), isolated in 1997
from the Bahamas, and DES/MB-
CAN97 (AY326358), isolated in 1997
from Manitoba, Canada (which also
belong to the international 1997–2000
RGI genotype). These findings indi-
cated that this rubella strain was circu-
lating in both Europe and North
America at least as early as 1997. 
Recent data indicate that interna-
tionally circulating rubella viruses
exist, even when vaccination pro-
grams are conducted. Comprehensive
specimen collection and genotypic
analysis are necessary to identify and
track the emergence and spread of
such genotypes.
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CTX-M 
β β-Lactamase–
producing
Escherichia coli in
Long-term Care
Facilities, France 
To the Editor: In long-term care
facilities, most endemic infections
affect respiratory and urinary tracts,
as well as skin and soft tissues (1–3).
Infection and colonization by antimi-
crobial-resistant organisms, in partic-
ular those producing plasmid-mediat-
ed extended-spectrum β-lactamases
(ESBL), are common in long-term
care facilities (4). Since 1984, ESBL-
producing  Enterobacteriaceae have
spread among French hospitals; with-
in Parisian public hospitals
(Assistance Publique, Hôpitaux de
Paris), ESBL-producing  Escherichia
coli is the most frequent species
found, representing 49.5% of 220
Enterobacteriaceae isolated in 2002,
mostly in urinary tract infections (5).
Among ESBL-producing Entero-
bacteriaceae, CTX-M–type β-lacta-
mases confer a higher level of resist-
ance to cefotaxime and ceftriaxone
than to ceftazidime. CTX-M–produc-
ing strains are endemic in Latin
America, Japan, and certain parts of
Eastern Europe; in contrast, these
strains are emerging in France,
Western Europe, and the United States
(6). We report the first documented
outbreak of CTX-M–producing E.
coli infection in a long-term care
facility in France. Our hospital is an
800-bed institution with 300 beds for
long-term patients distributed among
three units located in two buildings.
The outbreak occurred in a 35-bed
unit and involved 26 of 47 hospital-
ized patients from October 2001 to
March 2003. This facility hosts
patients for extended periods of time
or permanently. The index case was
identified in October 2001; the patient
had a urinary tract infection attributa-
ble to an ESBL-producing E. coli,
which showed resistance patterns not
previously found in our hospital.
Three new cases were detected within
the following 2 months, and all
patients had urinary tract infection
with the same pattern of resistance. In
January 2002, patients were screened
for ESBL-producing strains by rectal
swabbing and urine culture. The
results showed E. coli with a high
level of resistance to amoxicillin and
ticarcillin (MIC > 128 µg/mL), partial
restoration of susceptibility to these
agents by addition of clavulanic acid
(MIC = 16–32 µg/mL), and higher
resistance to cefotaxime (MIC > 128
µg/mL) than to ceftazidime (MIC =
32–64  µg/mL.) A cephalosporin/co-
amoxiclav synergy test was positive,
which suggests a CTX-M ESBL.
Strains were also resistant to
ciprofloxacin (MIC 64 µg/mL) and
gentamicin (MIC > 64  µg/mL) but
remained susceptible to trimethoprim-
sulfamethoxazole. 
Attempts to transfer resistance to
β-lactams by conjugation to E. coli
J53-2 with the 26 strains tested were
unsuccessful. In contrast, transfor-
mants were obtained with plasmid
DNA of the 19 strains tested by elec-
troporation. The transformants’ sus-
ceptibility pattern was similar to that
of the donor strains, except for
ciprofloxacin resistance. Analytical
isoelectric focusing showed that all
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